Psoriasis: mechanisms and entry points for possible therapeutic interventions.
Psoriasis is a heterogeneous disorder not only in regard to its variability in clinical expression and age at onset, but also in the degree to which genetic and immunological factors such as T cells and cytokines contribute. A Psoriasis Treatment Index' is proposed according to clinical severity and hence suggested treatment regimens. Recent and new treatments include FK 506, cyclosporin, a fusion protein of human interleukin 2 with fragments of diphtheria toxin, topical tumour necrosis factor inhibitors, topical retinoids, T cell receptor peptide vaccines and intercellular adhesion molecule 1 (ICAM-1) antisense oligonucleotides.
Christophers
E
E
Klinik fur Dermatologie, Venereologie und Allergologie, Universitats-Hautlinik, Kiel, Germany.
D002986:Clinical Trials as Topic; D016572:Cyclosporine / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D010778:Photochemotherapy; D011379:Prognosis; D011565:Psoriasis / Q000188:drug therapy* / Q000503:physiopathology; D016559:Tacrolimus / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D016559:Tacrolimus